Neeta P Pathe, MD
Alt: (724) 282-6175
Fax: (724) 482-1115
Business hours
| Monday | 9:00am to 4:00pm |
| Tuesday | 9:00am to 4:00pm |
| Wednesday | 9:00am to 4:00pm |
| Thursday | 9:00am to 4:00pm |
| Friday | 9:00am to 4:00pm |
| Saturday | - |
| Sunday | - |
About us
Neeta Pathe, MD is a medical oncologist with AHN Cancer Institute, specializing in the development of customized plans of care for patients with cancer and blood disorders. She applies best-practice techniques and procedures to help ensure long-term patient outcomes. Dr. Pathe went to medical school at Government Medical College in Maharashtra, India. She did her residency and her fellowship in hematology/oncology at West Penn Hospital in Pittsburgh, Pennsylvania. Dr. Pathe is certified by the American Board of Medical Oncology and Hematology and is affiliated with the American Society of Hematology and the American Society of Clinical Oncology. She welcomes patients ages 18 and older.
Call today!
| Languages | Marathi, Hindi, English |
| Services | lymphedema physical therapy, chemotherapy iv infusion, rectal neuroendocrine tumor, neuroendocrine carcinoma, metastatic neuroendocrine tumors, relapsed myeloma, colon adenocarcinoma, neutrophilia, elevated transferrin saturation, elevated ferritin, upper extremity lymphedema, metastatic blood cancers, neuroendocrine tumor of the lung, generalized lymphatic anomaly, adenocarcinoma of the bladder, hormone receptor negative breast cancer, fibrolamellar carcinoma, ductal carcinoma in situ (dcis), personal history of cancer, secondary cancer screening, long term side effects of cancer treatment, personal history of radiation therapy, personal history of chemotherapy, blood cancer chemotherapy, autoimmune neutropenia (ain), evans syndrome, hemophilia inhibitors, factor thirteen deficiency, factor seven deficiency, hereditary elliptocytosis (he), acquired elliptocytosis, prostate cancer chemotherapy, bladder cancer chemotherapy, testicular cancer chemotherapy, relapsed acute myelogenous leukemia (aml), breast cancer biological targeted therapy, relapsed non hodgkin lymphoma, relapsed hodgkin lymphoma, relapsed acute lymphoblastic leukemia (all), neutrophil disorders, blastic plasmacytoid dendritic cell neoplasm, disseminated intravascular coagulation, hormone receptor positive breast cancer, her2 positive breast cancer, carcinoma of unknown primary, lymphomatoid granulomatosis, intrathecal chemotherapy, maintenance chemotherapy, consolidation chemotherapy, induction chemotherapy, er negative breast cancer, pituitary cancer, chronic myelomonocytic leukemia, malignant adnexal tumor, peripheral t cell lymphoma, intraarterial chemotherapy of tumors, inflammatory breast cancer, recurrent breast cancer, brain metastases, coagulation disorders, bone marrow failure syndromes, waldenstrom macroglobulinemia, liver metastases, adrenal nodules, metastatic breast cancer, hodgkin lymphoma, triple negative breast cancer, cancer genetics, hemoglobinopathies, breast cancer therapy, thrombocytosis, acute blood loss anemia, blood disorders, lymphopenia, prostate cancer, early detection of cancer, von willebrand disease, adenocarcinoma of lung, acute myelogenous leukemia (aml), acute lymphoblastic leukemia (all), abdominal chemotherapy, breast cancer, multiple endocrine neoplasia type 2b, pernicious anemia, hemolytic anemia, retroperitoneal mass, acute promyelocytic leukemia, prolymphocytic leukemia, primary myelofibrosis, oral complications of cancer, non hodgkin lymphoma, myeloproliferative diseases, lymphoid leukemia, lymphedema therapy, large granular lymphocytic leukemia, hematologic malignancies, head and neck cancer, cancer related fatigue, hereditary cancer risk |